Edgewise Therapeutics Inc (EWTX) stock: 12-month forecast projects 160.16% potential return%

Edgewise Therapeutics Inc [EWTX] stock prices are down -2.23% to $18.45 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The EWTX shares have gain 12.16% over the last week, with a monthly amount drifted -11.51%, and not seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

From an analyst’s perspective:

Edgewise Therapeutics Inc [NASDAQ: EWTX] stock has seen the most recent analyst activity on March 07, 2024, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $48. On August 25, 2022, downgrade downgraded it’s rating to Sell but maintained its price target of $5 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $31 on April 13, 2022. Goldman initiated its recommendation with a Neutral and recommended $11 as its price target on January 28, 2022.

The stock price of Edgewise Therapeutics Inc [EWTX] has been fluctuating between $5.12 and $23.50 over the past year. Currently, Wall Street analysts expect the stock to reach $48 within the next 12 months. Edgewise Therapeutics Inc [NASDAQ: EWTX] shares were valued at $18.45 at the most recent close of the market. An investor can expect a potential return of 160.16% based on the average EWTX price forecast.

Analyzing the EWTX fundamentals

Gross Profit Margin for this corporation currently stands at 0.09% with Operating Profit Margin at -60.47%, Pretax Profit Margin comes in at -51.46%, and Net Profit Margin reading is -51.46%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.28 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.93 points at the first support level, and at 17.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.08, and for the 2nd resistance point, it is at 19.72.

Ratios To Look Out For

It’s worth pointing out that Edgewise Therapeutics Inc [NASDAQ:EWTX]’s Current Ratio is 30.24. Also, the Quick Ratio is 30.24, while the Cash Ratio stands at 2.53.

Transactions by insiders

Recent insider trading involved MOORE JOHN R, General Counsel, that happened on May 02 ’24 when 1956.0 shares were sold. Chief Financial Officer, Carruthers R Michael completed a deal on May 02 ’24 to sell 2157.0 shares. Meanwhile, Chief Business Officer Derakhshan Behrad sold 1718.0 shares on May 02 ’24.

Related Posts